Topics

Arthritis
Amgen fourth-quarter earnings, revenue beat estimates
Amgen fourth-quarter earnings, revenue beat estimates

Amgen Inc., the Thousand Oaks biopharmaceutical giant, said its fourth-quarter earnings jumped 27%, beating analysts' estimates, on strong sales of its arthritis drug Enbrel. The company, which also makes drugs to treat cancer, kidney disease, osteoporosis and anemia, said it earned $1.29 billion, or $1.68 a share, in the last three months of 2014, up from $1.02 billion, or $1.33, a year earlier. The company's stock, which closed Tuesday at $158.89, down 84 cents, rose about 1% in after-hours trading. Revenue for the quarter was $5.33 billion, a 6% year-over-year increase. Amgen, one of the largest employers in Southern California, twice announced job cuts last year as it...

Loading